DNPUF (Sumitomo Pharma Co) Ending Cash Position: $-82 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DNPUF Sumitomo Pharma Co Ltd DNPUF
65 GF Score
Price $8.41
GF Value $5.49
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Sumitomo Pharma Co Ending Cash Position?

Sumitomo Pharma Co DNPUF 65 Ending Cash Position is $-82 Mil as of Mar. 2026. GuruFocus rates DNPUF with a GF Score™ of 65/100 and a GF Value™ of $5.49 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Sumitomo Pharma Co's Ending Cash Position for the quarter that ended in Mar. 2026 was $-82 Mil.

Sumitomo Pharma Co's quarterly Ending Cash Position increased from Sep. 2025 ($122 Mil) to Dec. 2025 ($368 Mil) but then declined from Dec. 2025 ($368 Mil) to Mar. 2026 ($-82 Mil).

Sumitomo Pharma Co's annual Ending Cash Position declined from Mar. 2024 ($194 Mil) to Mar. 2025 ($155 Mil) but then increased from Mar. 2025 ($155 Mil) to Mar. 2026 ($279 Mil).

Sumitomo Pharma Co Ending Cash Position Related Terms

Sumitomo Pharma Co Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Sumitomo Pharma Co's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sumitomo Pharma Co Ending Cash Position Chart

Sumitomo Pharma Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,711.83 1,073.42 193.88 155.08 279.24

Sumitomo Pharma Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -417.81 141.56 121.99 367.66 -82.01
DNPUF
65GF Score
Sumitomo Pharma Co Ltd DNPUF
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sumitomo Pharma Co Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Sumitomo Pharma Co's Ending Cash Position for the fiscal year that ended in Mar. 2026 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=228.682+50.554
=279

Sumitomo Pharma Co's Ending Cash Position for the quarter that ended in Mar. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=-1.4210854715202E-14+-82.006
=-82

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $-82 Mil mean?
Sumitomo Pharma Co (DNPUF) has a Ending Cash Position of $-82 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Sumitomo Pharma Co and its competitors.
Is Sumitomo Pharma Co's Ending Cash Position too high?
Sumitomo Pharma Co's current Ending Cash Position is $-82 Mil. Overall, Sumitomo Pharma Co has a GF Score™ of 65/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sumitomo Pharma Co's Ending Cash Position compare to ZTS?
Sumitomo Pharma Co's Ending Cash Position of $-82 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Drug Manufacturers company?
A good Ending Cash Position depends on the Drug Manufacturers industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Sumitomo Pharma Co and its competitors. Sumitomo Pharma Co's current Ending Cash Position is $-82 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sumitomo Pharma Co stock overvalued right now?
Based on GuruFocus' analysis, Sumitomo Pharma Co (DNPUF) is currently considered Significantly Overvalued. The stock's GF Value™ is $5.49, compared to a current price of $8.41 — trading 53.1% above its estimated fair value. The current Ending Cash Position is $-82 Mil. Sumitomo Pharma Co's overall GF Score™ is 65/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Sumitomo Pharma Co (DNPUF), the current Ending Cash Position is $-82 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sumitomo Pharma Co (DNPUF) Overvalued in 2026?

Based on GuruFocus' analysis, Sumitomo Pharma Co stock appears to be overvalued. The current stock price of $8.41 is trading 53.1% above its estimated GF Value™ of $5.49. GuruFocus considers Sumitomo Pharma Co to be Significantly Overvalued.

Key valuation signals for DNPUF:

  • Ending Cash Position: $-82 Mil
  • GF Value™: $5.49 vs. price of $8.41 (53.1% above fair value)
  • GF Score™: 65/100 with 6 warning signs

No single metric tells the full story. See the DNPUF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sumitomo Pharma Co Business Description

Address 6-8, Doshomachi 2-chome, Chuo-ku, Osaka, JPN, 541-0045
Sumitomo Pharma Co Ltd is a specialty and generic drug manufacturing company. Sumitomo's vast majority of sales are generated in North America, followed by Japan. The company's core business is its pharmaceutical products business. The pharmaceutical business maintains a focus on a variety of areas, including cardiovascular/diabetes, psychiatry & neurology, and specialty areas. Sumitomo considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
65GF Score

Get the complete analysis for DNPUF

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$8.41
Price
$5.49
GF Value